Trends in patient characteristics, treatment and survival in breast cancer in a non-selected retrospective clinical cohort study of 2,600 patients

Archives of Gynecology and Obstetrics

Volumn 287, Issue 1, 2013, Pages 103-110

  Van Ewijk, R J G ^a   Schwentner, L ^b   Wockel A ^b   Konig J ^a   Kreienberg, R ^b   Blettner, M ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

Author keywords

Breast cancer; Epidemiology; Screening; Therapy; Treatment

Indexed keywords

AROMATASE INHIBITOR; GONADORELIN; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; ONCOGENE NEU; OVERALL SURVIVAL; PARTIAL MASTECTOMY; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; SURVIVAL TIME; TREND STUDY;

AGE FACTORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; COHORT STUDIES; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MENOPAUSE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SURGICAL PROCEDURES, OPERATIVE; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84872345128     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-012-2544-7     Document Type: Article

References (17)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer Statistics, 2010. CA Cancer J Clin 60:277-300
2. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781
3. Coleman MP, Forman D, Bryant H et al (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377:127-138
4. Holleczek B, Arndt V, Stegmaier C, Brenner H (2011) Trends in breast cancer survival in Germany from 1976 to 2008 - A period analysis by age and stage. Cancer Epidemiol 35(5):399-406
5. Goldhirsch A, Inle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 20:1319-1329
6. Biesheuvel C, Weigel S, Heindel W (2011) Mammography screening: evidence, history and current practice in Germany and other European countries. Breast Care 6(2):104-109
7. Goldhirsch A, Glick JH, Gelber RD, Senn H-J (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer I 90:1601-1608 (Pubitemid 28523434)
8. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn H-J (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21(17):3357-3365 (Pubitemid 46606270)
9. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn H-J (2001) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 19(18):3817-3827 (Pubitemid 32880060)
10. Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thürlimann B, Senn H-J (2006) First - select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 17(12):1772-1776 (Pubitemid 44884051)
11. Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologie 8(3):138-140
12. Statistisches Landesamt Baden-Württemberg, Stuttgart. Struktur- und Regionaldatenbank. http:\\www.statistik-bw.de/SRDB/, downloaded on 30 Aug 2011
13. Aydogan F, Gazioglu E, Canbay I, Aydin T, Aydogan C, Uras V, Celik A, Cengiz M, Ferahman M, Unal H (2011) What has changed in the management of breast cancer in the past 25 years at the Istanbul university hospital? JCO 29:(suppl 27:184)
14. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn H-J & Panel Members (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133-1144
15. Regierer AC, Wolters R, Kurzeder C, Wöckel A, Novopashenny I, Possinger K, Wischnewsky MB, Kreienberg R (2011) High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS? Breast Cancer Res Treat 128(1):273-281
16. Kwong A, Mang OW, Wong CH, Chau WW (2011) The Hong Kong Breast cancer research group, Law S.C. Breast cancer in Hong Kong, Southern China: The first population based analysis of epidemiological characteristics, stage-specific, cancer-specific, and disease free survival in breast cancer patients: 1997-2001. Ann Surg Oncol. doi: 10.1245/s10434-011-1960-4
17. Autier P, Boniol M, Gavin A, Vatten LJ (2011) Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 343:d4411